Tisotumab vedotin (TV, Tivdak®), the first ADC approved for the treatment of cervical cancer, consists of a human TF-specific mAb, a protease-cleavable linker, and the highly potent cytotoxic payload monomethyl auristatin E (MMAE)—a microtubule-disrupting agent (Breij et al., 2014), as shown in Figure 1. This evidence concerns the gene TF and cervical cancer.